BR0110403A - Administração de um composto quimioprotetor baseado em tiol - Google Patents

Administração de um composto quimioprotetor baseado em tiol

Info

Publication number
BR0110403A
BR0110403A BR0110403-9A BR0110403A BR0110403A BR 0110403 A BR0110403 A BR 0110403A BR 0110403 A BR0110403 A BR 0110403A BR 0110403 A BR0110403 A BR 0110403A
Authority
BR
Brazil
Prior art keywords
thiol
administration
chemoprotectant agent
intra
based chemoprotectant
Prior art date
Application number
BR0110403-9A
Other languages
English (en)
Inventor
Michael A Pagel
Leslie Muldoon
Edward A Neuwelt
Original Assignee
Univ Oregon Health Sciences
Us Gov Veterans Affairs
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Oregon Health Sciences, Us Gov Veterans Affairs filed Critical Univ Oregon Health Sciences
Publication of BR0110403A publication Critical patent/BR0110403A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A61K38/063—Glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Toxicology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

"ADMINISTRAçãO DE UM COMPOSTO QUIMIOPROTETOR BASEADO EM TIOL". Trata-se de um processo de administração de um agente quimioprotetor baseado em tiol incluindo NAC (N-acetil cisteina) e STS (tiossulfato de sódio) que acentuadamente afeta biodistribuição e protege contra dano a partir de procedimentos intra-arteriais diagnósticos ou terapêuticos. Um processo para tratamento ou mitigação de efeitos colaterais de terapia de câncer citotóxico para tumores localizados na cabeça ou pescoço e tumores de cérebro. o agente quimioprotetor baseado em tiol é administrado intra-arterialmente com rápida e primeira tomada de passe em órgãos e tecidos outros que não o fígado.
BR0110403-9A 2000-04-26 2001-04-26 Administração de um composto quimioprotetor baseado em tiol BR0110403A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US19993600P 2000-04-26 2000-04-26
US22987000P 2000-08-30 2000-08-30
PCT/US2001/040624 WO2001080832A2 (en) 2000-04-26 2001-04-26 Administration of a thiol-based chemoprotectant compound

Publications (1)

Publication Number Publication Date
BR0110403A true BR0110403A (pt) 2004-02-25

Family

ID=26895307

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0110403-9A BR0110403A (pt) 2000-04-26 2001-04-26 Administração de um composto quimioprotetor baseado em tiol

Country Status (13)

Country Link
US (6) US7022315B2 (pt)
EP (1) EP1328253B1 (pt)
JP (1) JP5242877B2 (pt)
KR (1) KR20030014208A (pt)
CN (1) CN1443064A (pt)
AT (1) ATE320793T1 (pt)
AU (2) AU5391901A (pt)
BR (1) BR0110403A (pt)
CA (1) CA2406081C (pt)
DE (1) DE60118172T2 (pt)
ES (1) ES2261399T3 (pt)
IL (1) IL152433A0 (pt)
WO (1) WO2001080832A2 (pt)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5391901A (en) 2000-04-26 2001-11-07 Univ Oregon Health Sciences Administration of a thiol-based chemoprotectant compound
ATE316786T1 (de) * 2000-11-22 2006-02-15 Rxkinetix Inc Behandlung von mukositis
US20040062764A1 (en) * 2001-08-30 2004-04-01 Neuwelt Edward A Chemoprotectant for gastric toxicity
EP1461033B1 (en) * 2001-11-29 2013-02-27 Sound Pharmaceuticals Incorporated Methods and compositions for ameliorating the undesirable effects of chemotherapy
DK1471902T3 (da) 2002-01-04 2014-09-08 Sound Pharmaceuticals Inc Sammensætninger til brug i fremgangsmåder til behandling af høretab
EP2420229A1 (en) * 2002-01-07 2012-02-22 Board Of Regents, University Of Texas System S-dimethylarsino-thiosuccinic acid s-dimethylarsino-2-thiobenzoic acid s-(dimethylarsino) glutathione as treatments for cancer
US20030235571A1 (en) * 2002-06-19 2003-12-25 Gabriel Gojon-Romanillos Systemic treatment of pathological conditions resulting from oxidative stress and/or redox imbalance
US6669929B1 (en) 2002-12-30 2003-12-30 Colgate Palmolive Company Dentifrice containing functional film flakes
US20040229815A1 (en) * 2003-01-03 2004-11-18 Nagasawa Herbert T. Methods for reducing oxidative stress in a cell with a sulfhydryl protected glutathione prodrug
US20040198841A1 (en) * 2003-03-13 2004-10-07 Oregon Health & Science University Use of thiol-based compositions in ameliorating mucosal injury
US20050118261A1 (en) * 2003-06-12 2005-06-02 Oien Hal J. Compositions and methods of administering doxepin to mucosal tissue
TW201440760A (zh) * 2004-07-16 2014-11-01 Texas A & M Univ Sys 有機砷化合物、其用於治療癌症之用途及包含其之醫藥組成物
US20070148154A1 (en) * 2004-12-17 2007-06-28 Universite Rene Descartes (Paris V) Use of superoxide dismutase mimetics and reductase gultatione in the form of anticancer drugs
WO2007027344A2 (en) 2005-07-29 2007-03-08 Ziopharm Oncology, Inc. Compounds and methods for the treatment of cancer
US8148356B2 (en) 2005-08-24 2012-04-03 Cumberland Pharmaceuticals, Inc. Acetylcysteine composition and uses therefor
DK1965787T3 (da) * 2005-11-30 2013-06-03 Endo Pharmaceuticals Inc Behandling af xerostomi med en svovlindeholdende antioxidant
WO2008021550A2 (en) * 2006-08-16 2008-02-21 Oregon Health & Science University Thiol-based agents for reducing toxicities associated with medical procedures employing radiographic contrast agents
TW200829261A (en) * 2006-09-29 2008-07-16 Ziopharm Oncology Inc Method for controlling angiogenesis in animals
US20100266501A1 (en) * 2006-11-07 2010-10-21 University Of Vermont and State Agricltural College Methods and compositions for organ protection
ES2392737T3 (es) * 2007-11-02 2012-12-13 Ziopharm Oncology, Inc. Terapia combinada con compuestos arsenicales orgánicos
CN101874034A (zh) * 2007-12-12 2010-10-27 Zio医药肿瘤学公司 用于治疗癌症的化合物和方法
AU2009214727B2 (en) * 2008-02-12 2014-12-11 Tosk, Incorporated Doxorubicin adjuvants to reduce toxicity and methods for using the same
DK2321012T3 (en) 2008-08-20 2018-12-03 Solasia Pharma K K ORGANIC RELATIONS AND PROCEDURES FOR TREATING CANCER
US20100183748A1 (en) * 2009-01-21 2010-07-22 Ikaria, Inc. Methods for Treating or Preventing Radiocontrast Agent Induced Kidney Injury
EP3213756A1 (en) * 2009-07-08 2017-09-06 Hope Medical Enterprise, Inc. D.b.a. Hope Pharmaceuticals Sodium thiosulfate-containing pharmaceutical compositions
DE102011006425A1 (de) 2010-03-31 2011-10-06 Awd.Pharma Gmbh & Co. Kg Pharmazeutische Zubereitung und deren Verwendung
JP6582983B2 (ja) * 2013-07-31 2019-10-02 味の素株式会社 癌化学療法時の副作用軽減剤
JP6763780B2 (ja) * 2014-05-12 2020-09-30 ザ・ジョンズ・ホプキンス・ユニバーシティー 合成脳浸透遺伝子ベクターの操作
CN117599029A (zh) 2016-03-17 2024-02-27 硫创治疗公司 用于控制释放半胱胺和系统治疗半胱胺敏感性病症的组合物
NZ756704A (en) 2017-03-08 2022-07-01 Hope Medical Entpr Inc Dba Hope Pharmaceuticals Intradialytic use of sodium thiosulfate
EP3684418A4 (en) 2017-09-20 2021-06-16 Thiogenesis Therapeutics, Inc. TREATMENT METHODS FOR CYSTEAMINE SENSITIVE CONDITIONS
US10596190B2 (en) * 2017-11-29 2020-03-24 Oregon Health & Science University Method for reducing ototoxicity in pediatric patients receiving platinum-based chemotherapy
WO2019157370A1 (en) 2018-02-09 2019-08-15 Decibel Therapeutics, Inc. Hypertonic pharmaceutical compositions containing an anti-platinum chemoprotectant agent
MA53102A (fr) 2018-07-03 2022-05-11 Fennec Pharmaceuticals Inc Formulations de thiosulfate de sodium anhydre
US20220016051A1 (en) * 2018-12-27 2022-01-20 Montefiore Medical Center Nucleophilic chemicals useful in the treatment of cisplatin-induced sensory neuropathy and ototoxicity
US10813947B1 (en) 2019-05-31 2020-10-27 Decibel Therapeutics, Inc. Methods of otoprotection against platinum-based antineoplastic agents
FR3099051A1 (fr) * 2019-07-25 2021-01-29 Laboratoires Grimberg Composition pour pulvérisation nasale ou buccale contenant du soufre
US20230068456A1 (en) * 2020-01-16 2023-03-02 The United States Of America, As Represented By The Secretary, Department Of Health And Human Servic Real-time monitoring of in vivo free radical scavengers through hyperpolarized n-acetyl cysteine isotopes
CN114848836B (zh) * 2021-07-06 2023-09-15 中山大学孙逸仙纪念医院 一种偶联物及其在治疗内耳疾病上的应用

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4474759A (en) * 1982-07-22 1984-10-02 Vojislav Petrovich Method of treating bacterial, viral or parasitic diseases
US4961926A (en) * 1987-11-19 1990-10-09 Sloan-Kettering Institute For Cancer Research Methods for prevention and treatment of mucositis with granulocyte colony stimulating factor
AU8948491A (en) 1990-11-09 1992-06-11 Cell Technology, Inc. Method for preventing drug-induced or radiation myelosuppression
IT1258781B (it) * 1992-01-16 1996-02-29 Zambon Spa Composizione farmaceutica oftalmica contenente n-acetilcisteina e polivinilalcol
US5618823A (en) * 1992-06-24 1997-04-08 Boehringer Mannheim Italia S.P.A. Glutathione as chemoprotective agent
US5424471A (en) * 1992-07-31 1995-06-13 U.S. Bioscience, Inc. Crystalline amifostine compositions and methods of the preparation and use of same
DE4228455A1 (de) * 1992-08-26 1994-09-15 Beiersdorf Ag Kosmetische und dermatologische Lichtschutzformulierungen mit einem Gehalt an Thiolen und/oder Thiolderivaten
US6214345B1 (en) 1993-05-14 2001-04-10 Bristol-Myers Squibb Co. Lysosomal enzyme-cleavable antitumor drug conjugates
US5843481A (en) * 1994-01-18 1998-12-01 Mount Sinai Hospital Corporation Treatment of proliferative disorders, metastasaes, and drug resistant tumors with vanadate compounds and derivatives or analogues thereof
US5789000A (en) 1994-11-14 1998-08-04 Bionumerik Pharmaceuticals, Inc. Sterile aqueous parenteral formulations of cis-diammine dichloro platinum
US5846958A (en) 1995-02-17 1998-12-08 U.S. Bioscience, Inc. Methods of using aminothiols to promote hematopoietic progenitor cell growth
US5643853A (en) * 1995-02-28 1997-07-01 Purdue Research Foundation Thiol activation of cytotoxic and auxin-herbicidal agents and root formation stimulation
US6110891A (en) * 1996-06-21 2000-08-29 Alizyme Therapeutics Ltd. Lectin compositions and uses thereof
DK0957920T3 (da) 1996-09-23 2002-04-02 Bionumerik Pharmaceuticals Inc Reduktion af carboplatins toksiske effekt under anvendelse af dithioethere
US6051563A (en) * 1997-02-12 2000-04-18 U.S. Bioscience, Inc. Methods for the administration of amifostine and related compounds
US6573253B2 (en) 1997-02-12 2003-06-03 Medimmune Oncology Inc. Methods for the administration of amifostine and related compounds
US5994409A (en) 1997-12-09 1999-11-30 U.S. Bioscience, Inc. Methods for treatment of neuro--and nephro--disorders and therapeutic toxicities using aminothiol compounds
US6231889B1 (en) * 1998-09-21 2001-05-15 Chronorx, Llc Unit dosage forms for the treatment of herpes simplex
AU5391901A (en) 2000-04-26 2001-11-07 Univ Oregon Health Sciences Administration of a thiol-based chemoprotectant compound
US6759061B2 (en) * 2001-08-31 2004-07-06 Renew Life, Inc. Liver function improvement formulation
EP1461033B1 (en) 2001-11-29 2013-02-27 Sound Pharmaceuticals Incorporated Methods and compositions for ameliorating the undesirable effects of chemotherapy
AU2003285128A1 (en) 2002-10-31 2004-05-25 Oregon Health And Science University Use of thiol-based compositions in treating chemotherapeutic agent-induced thrombocytopenia

Also Published As

Publication number Publication date
US20030176359A1 (en) 2003-09-18
ES2261399T3 (es) 2006-11-16
CA2406081A1 (en) 2001-11-01
EP1328253B1 (en) 2006-03-22
US20060177523A1 (en) 2006-08-10
ATE320793T1 (de) 2006-04-15
AU2001253919B2 (en) 2006-12-14
US7022315B2 (en) 2006-04-04
DE60118172D1 (de) 2006-05-11
US20170182089A1 (en) 2017-06-29
CN1443064A (zh) 2003-09-17
CA2406081C (en) 2009-12-22
EP1328253A2 (en) 2003-07-23
KR20030014208A (ko) 2003-02-15
US20160184353A1 (en) 2016-06-30
JP2003531164A (ja) 2003-10-21
US20200000844A1 (en) 2020-01-02
WO2001080832A3 (en) 2003-05-15
JP5242877B2 (ja) 2013-07-24
IL152433A0 (en) 2003-05-29
AU5391901A (en) 2001-11-07
WO2001080832A2 (en) 2001-11-01
US20180289737A1 (en) 2018-10-11
DE60118172T2 (de) 2007-03-08

Similar Documents

Publication Publication Date Title
BR0110403A (pt) Administração de um composto quimioprotetor baseado em tiol
WO2000041726A3 (en) Noninvasive vascular therapy
BR9815442A (pt) Liberação terapêutica dirigida de compostos de vitamina d
Wang et al. Photodynamic therapy utilising topical�-aminolevulinic acid in non-melanoma skin malignancies of the eyelid and the periocular skin
BR0209365A (pt) Usos farmacêuticos de bisfosfonatos
JP2003531164A5 (pt)
HK1046093A1 (en) Docetaxel in combination with rhumab her2 for the treatment of cancers.
US20030028227A1 (en) Locally confined photodynamic treatment for diseased tissue
AU678341B2 (en) Method for hyperthermic potentiation of tissue
BR9715022A (pt) Método para tratar de doenças prostáticas usando formulações de vitamina d por liberação sistemática e/ou prolongada
CA2442168A1 (en) N-acetylcysteine compositions and methods for the treatment and prevention of drug toxicity
BRPI0517953A (pt) uso de zd 6474, ou de um sal farmaceuticamente aceitável do mesmo, e de um antiandrógeno, composição farmacêutica, kit, e, método para a produção de um efeito da redução da permeabilidade vascular e/ou antiangiogênico em um animal de sangue quente
CA2208206A1 (en) Composition for treating tumors comprising lactose and a saccharide conjugate of a cytotoxic phenolic compound
AU3842989A (en) Conjugates for bone imaging and bone cancer therapy
BR0313117A (pt) Método para a produção de um efeito redutor de permeabilidade vascular e/ou antiangiogênico em um animal de sangue quente tal como um humano, método para o tratamento de um câncer em um animal de sangue quente tal como um humano, composição farmacêutica, kit, e, uso de zd6474 ou de um seu sal farmaceuticamente aceitável e de zd1839 ou de um seu sal farmaceuticamente aceitável
BR9813318A (pt) Processo de tratamento de tumores e degeneração macular em paciente humano ou veterinário, composição farmacêutica para tratamento de tumores e degeneração macular em um paciente humano ou veterinário
BR8905657A (pt) Processo para preparar um quelante bifuncional,processo para preparar um complexo de um composto,processo para preparar um conjugado e processo para preparar uma formulacao farmaceutica
Coleman Should bisphosphonates be the treatment of choice for metastatic bone disease?
DE69835461D1 (de) Anti-arrhythmische Zusammensetzungen und Behandlungsverfahren
BR0110150A (pt) Método e composição para o tratamento de câncer por meio da administração de agentes quimioterápicos indutores da apoptose
Cheli et al. Photodynamic therapy of spontaneous animal tumors using the active component of hematoporphyrin derivative (DHE) as photosensitizing drug: Clincal results
Kaplan et al. Mitomycin and fluorouracil with concomitant radiotherapy in head and neck cancer
BRPI0515668A (pt) tratamento de osteoporose induzida por privação de androgênio
Kuefer et al. Papillary thyroid carcinoma: demographics, treatment, and outcome in eleven pediatric patients treated at a single institution
KR927002224A (ko) 항종양효과증강제 및 항종양제

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]